200,000+ products from a single source!

sales@angenechem.com

Home > Imidazoles > 1021937-07-4

1021937-07-4

1021937-07-4 | Pyridine, 2-[4-[2-[5-(2,2-dimethylbutyl)-1H-imidazol-2-yl]ethyl]phenyl]-

CAS No: 1021937-07-4 Catalog No: AG0006V0 MDL No:MFCD22419392

Product Description

Catalog Number:
AG0006V0
Chemical Name:
Pyridine, 2-[4-[2-[5-(2,2-dimethylbutyl)-1H-imidazol-2-yl]ethyl]phenyl]-
CAS Number:
1021937-07-4
Molecular Formula:
C22H27N3
Molecular Weight:
333.4699
MDL Number:
MFCD22419392
IUPAC Name:
2-[4-[2-[5-(2,2-dimethylbutyl)-1H-imidazol-2-yl]ethyl]phenyl]pyridine
InChI:
InChI=1S/C22H27N3/c1-4-22(2,3)15-19-16-24-21(25-19)13-10-17-8-11-18(12-9-17)20-7-5-6-14-23-20/h5-9,11-12,14,16H,4,10,13,15H2,1-3H3,(H,24,25)
InChI Key:
WVAKRQOMAINQPU-UHFFFAOYSA-N
SMILES:
CCC(Cc1cnc([nH]1)CCc1ccc(cc1)c1ccccn1)(C)C

Properties

Complexity:
387  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
333.22g/mol
Formal Charge:
0
Heavy Atom Count:
25  
Hydrogen Bond Acceptor Count:
2  
Hydrogen Bond Donor Count:
1  
Isotope Atom Count:
0
Molecular Weight:
333.479g/mol
Monoisotopic Mass:
333.22g/mol
Rotatable Bond Count:
7  
Topological Polar Surface Area:
41.6A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
5.5  

Literature

Title Journal
Discovery of benzodiazepine sulfonamide-based bombesin receptor subtype 3 agonists and their unusual chirality. ACS medicinal chemistry letters 20111208
Discovery of MK-5046, a Potent, Selective Bombesin Receptor Subtype-3 Agonist for the Treatment of Obesity. ACS medicinal chemistry letters 20110113
Synthesis and SAR of derivatives based on 2-biarylethylimidazole as bombesin receptor subtype-3 (BRS-3) agonists for the treatment of obesity. Bioorganic & medicinal chemistry letters 20100401
Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity. Cell metabolism 20100203

Related Products

© 2019 Angene International Limited. All rights Reserved.